Severe sepsis and septic shock: Defining the clinical problem

Scandinavian Journal of Infectious Diseases

Volumn 35, Issue 9, 2003, Pages 529-534

  Opal, Steven M ^a,b  

^a BROWN UNIVERSITY   (United States)

^b MEMORIAL HOSPITAL OF RHODE ISLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACCURACY; AGE; ARTICLE; CLINICAL MEDICINE; DISEASE PREDISPOSITION; DISEASE SEVERITY; HUMAN; IMMUNOLOGY; INFLAMMATION; MEDICAL RESEARCH; MICROORGANISM; MORTALITY; MULTIPLE ORGAN FAILURE; NOMENCLATURE; SEPSIS; SEPTIC SHOCK; STAGING; STANDARDIZATION; STATISTICS; SYNDROME;

ADULT; AGED; FEMALE; HUMANS; MALE; MIDDLE AGED; SEPSIS; SEVERITY OF ILLNESS INDEX; SHOCK, SEPTIC; TERMINOLOGY;

EID: 0242320242     PISSN: 00365548     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365540310015917     Document Type: Article

References (39)

1. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979-2000. N Engl J Med 2003; 348: 1546-54.
2. Alberti C, Brun-Buisson C, Burchardi H, Martin C, Goodman S, Artigas A, et al. Epidemiology of sepsis and infection in ICU patients from international multicenter cohort study. Intensive Care Med 2002; 28: 108-21.
3. Abraham E, Matthay MA, Dinarello CA, Vincent JL, Cohen J, Opal SM, et al. Consensus Conference Definitions for sepsis, acute lung injury, and ARDS - time for reevaluation. Crit Care Med 2000; 28: 232-6.
4. Opal SM, Cross AS. Clinical trials for sepsis: past failures and future hopes. Infect Dis Clinics North Am 1999; 13: 285-98.
5. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, et al. The 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003; 31: 1250-6.
6. Members of the ACCP/CCM Consensus Conference Committee. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies for sepsis. Crit Care Med 1992; 20: 864-74.
7. Marshall JC. SIRS and MODS: what is their relevance to the science and practice of intensive care? Shock 2000; 14: 586-89.
8. Vincent J-L. Dear SIRS, I'm sorry to say that I don't like you. Crit Care Med 1997; 25: 372-4.
9. Ramsey G, Garlach H, Levy MM. An international sepsis survey: a study of doctors' knowledge and perception about sepsis. Crit Care Med 2003; 31 (in press).
10. Rangel-Frausto MS, Pittet D, Costigan W, Hwang D, Davis CS, Wenzel RP. The natural history of the systemic inflammatory response syndrome (SIRS): a prospective study JAMA 1995; 273: 117-23.
11. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29: 1303-10.
12. Valles J, Leon C, Alvarez-Lerma F. Nosocomial bacteremia in critically ill patients: a multicenter study evaluating epidemiology and prognosis. Spanish Collaborative Group for Infections in Intensive Care Units of the Sociedad Espanola de Medicina Intensiva Unidades Coronarias (SEMIUC). Clin Infect Dis 1997; 24: 387-95.
13. Sands KE, Bates DW, Lanken PN, Graman PS, Hibbend PL, Kahn KL, Parsonnet J, Panzer R, Orav EJ, Snydman DR. Epidemiology of sepsis syndrome in eight academic medical centers. JAMA 1997; 278: 234-40.
14. Kieft H, Hoepelman AI, Zhou W, Rozenberg-Arka M, Struyvenberg A, Verhoef J. The sepsis syndrome in a Dutch university hospital: clinical observations. Arch Intern Med 1993; 153: 2241-7.
15. Brun-Buisson C. The epidemiology of the systemic inflammatory response syndrome. Intensive Care Med 2000; 26(Suppl 1): S64-74.
16. Wenzel RP, Edmound MB. Severe sepsis - national estimates. Crit Care Med 2001; 29: 1472-4.
17. Eaton S, Burnham E, Martin GS, Moss M. The ICD-9 code for septicemia maintains a high positive predictive value for clinical sepsis (Abstract). Am J Respir Crit Care Med 2002; 165: A471.
18. Heddrewick SA, Lyons MJ, Liu M, Vazquez JA, Kauffman CA. Epidemiology of yeast colonization in the intensive care unit. Euro J Clin Microbiol Infect Dis 2000; 19: 663-0.
19. Opal SM, Maki D, LaRosa, S, Garber G, Dhainaut JF, Graham D, et al. Systemic host response to sepsis based upon the infection microorganism and effects of drotecogin alfa activated. Clin Infect Dis 2003; 37: 50-8.
20. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med 2003; 348: 138-50.
21. Groeneveld ABJ, Tacx AC, Bosinik AWJ, van Mierlo GJ, Hack CE. Circulating inflammatory mediators predict shock and mortality in febrile patients with microbial infection. Clin Immunol 2003; 106: 106-15.
22. Sorensen IA, Nielsen GG, Andersen PK, Teasdale TW. Genetic and environmental influences on premature death in adult adoptees. N Engl J Med 1988; 318: 727-32.
23. Angus DC, Burgner D, Wunderink R, Mira J-P, Gerlach H, Wiedermann CJ, Vincent J-L. The PIRO concept: P is for predisposition. Crit Care 2003; 7: 248-51.
24. Stuber F, Petersen M, Bokelmann F, Schade U. A genomic polymorphism within the tumor necrosis factor locus influences plasma tumor necrosis factor-alpha concentrations in outcome of patients with severe sepsis. Crit Care Med 1996; 24: 381-4.
25. Mira JP, Cariou A, Grall F, Delclaux C, Losser M-R, Heshmati F, Cheval C, Monchi M, Teboul J-L, Riche F, Leleu G, Arbibe L, Mignon A, Delpech M, Dhainaut J-F. Association of TNF2, a TNF-alpha promoter polymorphism, with septic shock susceptibility and mortality: a multicenter study. JAMA 1999; 282: 561-8.
26. Fang XM, Schroeder S, Hoeft A, Stuber F. Comparison of two polymorphisms of the interleukin-1 gene family: interleukin-1 receptor antagonist polymorphism contributes to susceptibility to severe sepsis. Crit Care Med 1999; 27: 1330-4.
27. Arbour NC, Lorenz E, Schutte BC, Zabner BC, Kline JN, Jones M, Frees K, Watt JL, Schwartz DA. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet 2000; 25: 187-91.
28. Lorenz E, Mira JP, Frees KL, Schwartz DA. Relevance of mutations of the TLR4 receptor in patients with Gram-negative septic shock. Arch Intern Med 2002; 162: 1028-31.
29. Gibot S, Cariou A, Drouet L, Rossingnol M, Ripoll L. Association between a genomic polymorphism with the CD14 locus in septic shock susceptibility and mortality rate. Crit Care Med 2002; 30: 969-73.
30. Merino J, Rodriguez-Valverde V, Lamelas JA, Riestra JL, Casanueva B. Prevalence of deficits of complement components in patients with recurrent meningococcal infections. J Infect Dis 1983; 148: 331-8.
31. Westendorp RGJ, Langermans JAM, Huizinga TWJ, Elouali AH, Verweij CL, Boomsma DI, Vandenbroake JP. Genetic influence on cytokine production and fatal meningococcal disease. Lancet 1997; 349: 170-3.
32. Platonov AE, Shipulin GA, Vershinina IV, Dankert J, van deWinkel JGJ, Kuijper EJ. Association of human FcγRIIa (CD32) polymorphism with susceptibility to and severity of meningococcal disease. Clin Infect Dis 1998; 27: 746-50.
33. Neth O, Hann I, Turner MW, Klein NJ. Deficiency of mannose-binding lectin and burden of infection in children with malignancy: a prospective study. Lancet 2001; 358: 614-8.
34. Hibberd ML, Sumiya M, Summerfield JA, Booy R, Levin M. Meningococcal Research Group. Association of variants of the gene for mannose-binding lectin with susceptibility to meningococcal disease. Lancet 1999; 353: 1049-52.
35. Roy S, Knox K, Segal S, Griffiths D, Moore CE, Welsh KI, et al. MBL genotype and risk of invasive pneumococcal disease: a case-control study Lancet 2002; 359: 1569-73.
36. Hermans PWM, Hibberd ML, Booy R, Daramola D, Hazelzet JA, deGroot R, Levin M. Meningococcal Research Group. 4G-5G promoter polymorphism in the plasminogen-activator-inhibitor-1 gene and outcome of meningococcal disease. Lancet 1999; 354: 556-60.
37. Vincent J-L, Opal S, Torres A, Bonten M, Cohen J, Wunderink R. The PIRO concept: I is for infection. Crit Care 2003; 7: 252-5.
38. Opal SM, Cohen J. Clinical gram-positive sepsis: does it fundamentally differ from gram-negative bacterial sepsis. Crit Care Med 1999; 27: 1608-16.
39. YU TD, Black E, Sands KE, Sanford Schwartz J, Hibberd PL, Graman PS, et al., for the Academic Medical Center Consortium Sepsis Project Working Group. Severe sepsis: variation in resource and therapeutic modality use among academic centers. Crit Care 2003; 7(3): R24-34.